Dear Valued Clients:
Caprion continues to effectively advance and evolve our services to meet the needs of our pharmaceutical and biotech clients.
Recently, we have changed the name of our exclusive proteomics platform from CellCarta® to ProteoCarta™. This simple and logical name change better represents Caprion’s expertise, track record, and heritage in proteomics-based biomarker discovery and validation. Our new name signifies the broadening and increasingly actionable information that our flagship service provides.
Please feel free to contact me with any questions or concerns. Thank you for trusting in Caprion and ProteoCarta to help advance your pipeline through proteomics.
Carol Berry, MBA
Chief Business Officer